Lynparza is co-developed and co-marketed by Merck and AstraZeneca. Credit: The Institute of Cancer Research.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting approval for AstraZeneca and Merck’s (MSD outside the US and Canada) Lynparza (olaparib) as adjuvant therapy for high-risk early breast cancer patients.

The treatment is intended for breast cancer patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative who have previously received neoadjuvant or adjuvant chemotherapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A PARP inhibitor, Lynparza is co-developed and co-marketed by Merck and AstraZeneca.

The CHMP adopted a positive opinion based on findings from the global, parallel-group, placebo-controlled, double-blind Phase III OlympiA clinical trial.

The trial analysed the safety and efficacy of Lynparza compared to placebo as adjuvant therapy for gBRCAm, HER2-negative high-risk early breast cancer patients. 

According to the results, Lynparza offered a statistically significant and clinically meaningful improvement in the primary endpoint of invasive disease-free survival (IDFS).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It showed a 42% decline in the risk of invasive breast cancer recurrences, second cancers or mortality compared to placebo. 

The treatment with Lynparza also provided a statistically significant and clinically meaningful improvement in the secondary endpoint of overall survival, offering a 32% decline in mortality risk versus placebo. 

Lynparza’s safety and tolerability profile in the trial was consistent with those reported in previous studies. 

Merck Research Laboratories global clinical development head, senior vice-president and chief medical officer Dr Eliav Barr said: “Patients with germline BRCA-mutated, HER2-negative early breast cancer will often develop breast cancer at an earlier age than those without BRCA mutations, impacting people in their prime. 

“The positive opinion brings us closer to our goal of offering a much-needed new treatment option to these patients in Europe.”

In November 2020, Lynparza (olaparib) received approval from the European Commission for treating prostate cancer and ovarian cancer in the EU.